Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer.

Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer.
复制标题

DOI:
10.1038/mtna.2013.14
复制
发表时间:
2013-04-16
期刊:
Molecular therapy. Nucleic acids
影响因子:
--
通讯作者:
--
中科院分区:
其他
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

MicroRNA-29b (miR-29b) 的表达已被证明在非小细胞肺癌 (NSCLC) 组织中降低。在此,我们确定癌基因细胞周期蛋白依赖性蛋白激酶 6 (CDK6) 是肺癌中 miR-29b 的直接靶标。我们假设,体内恢复 miR-29b 并因此靶向对肿瘤发生和进展重要的基因可能代表肺癌治疗的一种选择。我们开发了一种基于阳离子脂质复合物 (LP) 的载体,可在体外和体内有效递送 miR-29b。含有 miR-29b (LP-miR-29b) 的 LP 有效地将 miR-29b 递送至 NSCLC A549 细胞,降低关键靶标 CDK6、DNMT3B 和骨髓细胞白血病序列 1 (MCL1) 的表达,以及 A549 细胞的细胞生长和克隆形成。此外,经 miR-29b 处理的细胞中顺铂的 IC50 有效降低。在异种移植鼠模型中,LPs在肿瘤部位有效积累。与 LP-miR-NC(阴性对照)相比,全身递送 LP-miR-29b 使肿瘤 miR-29b 表达增加约五倍,将 CDK6、DNMT3B 和 MCL1 的肿瘤 mRNA 表达分别下调约 57.4%、约 40.5 和约 52.4%,并显着抑制肿瘤生长约 60%。我们的结果表明,阳离子 LP 代表了一种有效的递送系统,在开发基于 miRNA 的肺癌治疗方法方面具有巨大潜力。
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small–cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo restoration of miR-29b and thus targeting of genes important to tumor initiation and progression may represent an option for lung cancer treatment. We developed a cationic lipoplexes (LPs)-based carrier that efficiently delivered miR-29b both in vitro and in vivo. LPs containing miR-29b (LP-miR-29b) efficiently delivered miR-29b to NSCLC A549 cells, reduced the expression of key targets CDK6, DNMT3B, and myeloid cell leukemia sequence 1 (MCL1), as well as cell growth and clonogenicity of A549 cells. In addition, the IC50 for cisplatin in the miR-29b–treated cells was effectively reduced. In a xenograft murine model, LPs efficiently accumulated at tumor sites. Systemic delivery of LP-miR-29b increased the tumor miR-29b expression by approximately fivefold, downregulated the tumor mRNA expression of CDK6, DNMT3B, and MCL1 by ~57.4, ~40.5, and ~52.4%, respectively, and significantly inhibited tumor growth by ~60% compared with LP-miR-NC (negative control). Our results demonstrate that cationic LPs represent an efficient delivery system that holds great potential in the development of miRNA-based therapeutics for lung cancer treatment.
DOI: 10.1038/nature03702
发表时间: 2005-06-09
期刊: NATURE
影响因子: 64.8
作者:
Lu, J;Getz, G;Golub, TR
通讯作者: Golub, TR
DOI: 10.1038/sj.onc.1210436
发表时间: 2007-09-13
期刊: ONCOGENE
影响因子: 8
作者:
Mott, J. L.;Kobayashi, S.;Gores, G. J.
通讯作者: Gores, G. J.
DOI: 10.1002/hep.23380
发表时间: 2010-03-01
期刊: HEPATOLOGY
影响因子: 13.5
作者:
Xiong, Yujuan;Fang, Jian-Hong;Zhuang, Shi-Mei
通讯作者: Zhuang, Shi-Mei
DOI: 10.1021/mp2002076
发表时间: 2011-08-01
影响因子: 4.9
作者:
Wu Y;Crawford M;Yu B;Mao Y;Nana-Sinkam SP;Lee LJ
通讯作者: Lee LJ
DOI: 10.1073/pnas.0707628104
发表时间: 2007-10-02
影响因子: 11.1
作者:
Fabbri, Muller;Garzon, Ramiro;Croce, Carlo M.
通讯作者: Croce, Carlo M.